Overview

Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB

Status:
Not yet recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

This study aims to find an optimized initial regimen for pulmonary tuberculosis(PTB), evaluating the efficacy, safety and acceptability of isoniazid, rifampicin and moxifloxacin(HRM) for the intensive phase of initial therapy of PTB, compared with the standard initial regimen.

Phase:

N/A

Details

Lead Sponsor:

Fifth Affiliated Hospital, Sun Yat-Sen University

Treatments:

Ethambutol
Isoniazid
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Pyrazinamide
Rifampin